Artist collective brings carbon-absorbing murals to Houston

WHEN FINE ART MEETS FRESH AIR

For 713 Day, UXD created carbon-absorbing mural "(HUE)STON HARMONY" in collaboration with Downtown Houston+ and local artist David Maldonado. Photo courtesy of Egidio Narvaez

Anthony Rose, the CEO of creative agency United By Design, is on a mission to brighten Houston’s urban spaces and improve the city’s air quality one carbon-absorbing mural at a time.

Rose originally founded United By Design, or UXD, in 2019 to connect muralists like himself and commercial businesses seeking to beautify their spaces and form brand identities. After creating vibrant murals for Lockhart Elementary School, the Houston Astros, and Smoothie King, Rose expanded UXD’s vision to include environmental sustainability in their artistic collaborations in 2022.

“This city’s vibrant art scene and growing focus on sustainability makes it an ideal location for our projects,” Rose says. “We’re not just creating eco-friendly murals, we’re reimagining how art can actively contribute to environmental solutions.”

In search of ecologically-conscious paints, Rose formed a partnership with Spain-based, natural paint company Graphenstone. Rose says he was drawn to the company’s eponymous Graphenstone coating because of its nontoxic ingredients and exclusively uses the product for UXD’s carbon-absorbing murals.

"Between Land and Sky" by artist David Maldonado was UXD's first carbon-absorbing painting. Photo courtesy of Dario DeLeon and Tommy Valdez

The Graphenstone coating consists of a limestone base which goes through a process called photocatalysis, during which carbon dioxide from the atmosphere is absorbed into the surface, and is then sealed in with graphene, a thin layer of carbon atoms. The murals absorb carbon dioxide throughout the coat’s drying process which typically takes 30 days.

“Each of our murals absorbs about 1600 grams of CO2 during that curing process which is the equivalent daily absorption of about 33 growing trees,” Rose explains.

UXD’s largest carbon-absorbing mural to date is a floor-to-ceiling panorama in downtown Houston’s historic Mellie Esperson building, home to the company’s new creative hub. Painted by Houston-born artist Emily Ding, the mural is a tribute to the establishment’s namesake: an innovative, early 20th century entrepreneur who constructed the opulent building.

"Future's Past" by Emily Ding in partnership with UXD tells the story of the Mellie Esperson building. Photo courtesy of Dario DeLeon

Rose says UXD plans to expand their carbon-absorbing murals project in collaboration with more local artists and establishments, while creating an artist-in-residency program themed around sustainability. Though Rose acknowledges in the grand scheme of carbon pollution these murals are not a silver bullet, he says the non-toxic paints are encouraging conversations about how artists can be conservation-minded.

“We’re trying to figure out how art as a messaging tool can help break down scientific data, a language not many people practice daily, can break down barriers and help bridge the gap to a more intuitive knowledge of sustainability,” Rose says. “We’re bringing the community together, helping them feel empowered, and giving them actionable information to help them live more sustainable lives.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."